RESEARKA

As this is a trial protocol for a planned study, no quantitative efficacy findings are available from this source. The study is designed to assess the direct effect of the mTOR inhibitor everolimus, alone and in combination with exercise, on a biomarker of skeletal aging. The lack of reported p-values, effect sizes, or interim results means the evidence base for healthspan outcomes in humans from this corpus is currently defined by the trial's design parameters rather than its conclusions. The study's focus on a specific, measurable healthspan component—bone mineral density—highlights a targeted approach to evaluating mTOR pathway modulation.

Citation Support

• source_1 Moel 2025
• source_2 Gkioni 2025
• source_3 Smiaek 2023
• source_4 Willows 2023
• source_5 Harinath 2025